267 related articles for article (PubMed ID: 29605436)
1. The role of ZA channel water-mediated interactions in the design of bromodomain-selective BET inhibitors.
Bharatham N; Slavish PJ; Shadrick WR; Young BM; Shelat AA
J Mol Graph Model; 2018 May; 81():197-210. PubMed ID: 29605436
[TBL] [Abstract][Full Text] [Related]
2. Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors.
Shadrick WR; Slavish PJ; Chai SC; Waddell B; Connelly M; Low JA; Tallant C; Young BM; Bharatham N; Knapp S; Boyd VA; Morfouace M; Roussel MF; Chen T; Lee RE; Kiplin Guy R; Shelat AA; Potter PM
Bioorg Med Chem; 2018 Jan; 26(1):25-36. PubMed ID: 29170024
[TBL] [Abstract][Full Text] [Related]
3. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations.
Wang Q; Li Y; Xu J; Wang Y; Leung EL; Liu L; Yao X
Sci Rep; 2017 Aug; 7(1):8857. PubMed ID: 28821780
[TBL] [Abstract][Full Text] [Related]
5. Solution structure of the second bromodomain of Brd2 and its specific interaction with acetylated histone tails.
Huang H; Zhang J; Shen W; Wang X; Wu J; Wu J; Shi Y
BMC Struct Biol; 2007 Sep; 7():57. PubMed ID: 17848202
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
[TBL] [Abstract][Full Text] [Related]
7. Deciphering the mechanisms of selective inhibition for the tandem BD1/BD2 in the BET-bromodomain family.
Cheng C; Diao H; Zhang F; Wang Y; Wang K; Wu R
Phys Chem Chem Phys; 2017 Sep; 19(35):23934-23941. PubMed ID: 28849824
[TBL] [Abstract][Full Text] [Related]
8. Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections.
Modukuri RK; Yu Z; Tan Z; Ta HM; Ucisik MN; Jin Z; Anglin JL; Sharma KL; Nyshadham P; Li F; Riehle K; Faver JC; Duong K; Nagarajan S; Simmons N; Palmer SS; Teng M; Young DW; Yi JS; Kim C; Matzuk MM
Proc Natl Acad Sci U S A; 2022 May; 119(22):e2122506119. PubMed ID: 35622893
[TBL] [Abstract][Full Text] [Related]
9. RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
Kharenko OA; Gesner EM; Patel RG; Norek K; White A; Fontano E; Suto RK; Young PR; McLure KG; Hansen HC
Biochem Biophys Res Commun; 2016 Aug; 477(1):62-67. PubMed ID: 27282480
[TBL] [Abstract][Full Text] [Related]
10. Dihydropyridine Lactam Analogs Targeting BET Bromodomains.
Jiang J; Sigua LH; Chan A; Kalra P; Pomerantz WCK; Schönbrunn E; Qi J; Georg GI
ChemMedChem; 2022 Jan; 17(1):e202100407. PubMed ID: 34932262
[TBL] [Abstract][Full Text] [Related]
11. Bromodomain Interactions with Acetylated Histone 4 Peptides in the BRD4 Tandem Domain: Effects on Domain Dynamics and Internal Flexibility.
Wernersson S; Bobby R; Flavell L; Milbradt AG; Holdgate GA; Embrey KJ; Akke M
Biochemistry; 2022 Nov; 61(21):2303-2318. PubMed ID: 36215732
[TBL] [Abstract][Full Text] [Related]
12. Insights into the crystal structure of BRD2-BD2 - phenanthridinone complex and theoretical studies on phenanthridinone analogs.
Mathur S; Deshmukh P; Tripathi S; Marimuthu P; Padmanabhan B
J Biomol Struct Dyn; 2018 Jul; 36(9):2342-2360. PubMed ID: 28696179
[TBL] [Abstract][Full Text] [Related]
13. Computational study on the selective inhibition mechanism of MS402 to the first and second bromodomains of BRD4.
Wang Q; Li Y; Xu J; Wang Y; Shi D; Liu L; Leung EL; Yao X
Proteins; 2019 Jan; 87(1):3-11. PubMed ID: 30260047
[TBL] [Abstract][Full Text] [Related]
14. The binding mechanism of NHWD-870 to bromodomain-containing protein 4 based on molecular dynamics simulations and free energy calculation.
Shi M; He J; Weng T; Shi N; Qi W; Guo Y; Chen T; Chen L; Xu D
Phys Chem Chem Phys; 2022 Feb; 24(8):5125-5137. PubMed ID: 35156677
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the human BRD2 bromodomain: insights into dimerization and recognition of acetylated histone H4.
Nakamura Y; Umehara T; Nakano K; Jang MK; Shirouzu M; Morita S; Uda-Tochio H; Hamana H; Terada T; Adachi N; Matsumoto T; Tanaka A; Horikoshi M; Ozato K; Padmanabhan B; Yokoyama S
J Biol Chem; 2007 Feb; 282(6):4193-201. PubMed ID: 17148447
[TBL] [Abstract][Full Text] [Related]
16. Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
Wellaway CR; Bamborough P; Bernard SG; Chung CW; Craggs PD; Cutler L; Demont EH; Evans JP; Gordon L; Karamshi B; Lewis AJ; Lindon MJ; Mitchell DJ; Rioja I; Soden PE; Taylor S; Watson RJ; Willis R; Woolven JM; Wyspiańska BS; Kerr WJ; Prinjha RK
J Med Chem; 2020 Sep; 63(17):9020-9044. PubMed ID: 32787145
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
18. Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins.
Fu Y; Zhang Y; Sun H
Eur J Med Chem; 2021 Dec; 226():113853. PubMed ID: 34547507
[TBL] [Abstract][Full Text] [Related]
19. In silico study directed towards identification of novel high-affinity inhibitors targeting an oncogenic protein: BRD4-BD1.
Tumdam R; Kumar A; Subbarao N; Balaji BS
SAR QSAR Environ Res; 2018 Dec; 29(12):975-996. PubMed ID: 30411639
[TBL] [Abstract][Full Text] [Related]
20. BETting on next-generation bromodomain inhibitors.
Collins MK; Chau CH; Price DK; Figg WD
Am J Clin Exp Urol; 2020; 8(4):129-132. PubMed ID: 32929408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
